Exane Derivatives’s Moderna MRNA Stock Holding History

Exane Derivatives’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$609K	Buy	4,267 +350	+9%	+$50K	0.35%	64
2022 Q1	$675K	Sell	3,917 -14	-0.4%	-$2.36K	0.19%	138
2021 Q4	$998K	Buy	3,931 +1,577	+67%	+$461K	0.24%	94
2021 Q3	$906K	Sell	2,354 -139	-6%	-$51.3K	0.22%	98
2021 Q2	$586K	Sell	2,493 -6,262	-72%	-$1.12M	0.13%	154
2021 Q1	$1.15M	Buy	8,755 +6,227	+246%	+$902K	0.33%	69
2020 Q4	$264K	Buy	2,528 +178	+8%	+$18K	0.08%	266
2020 Q3	$166K	Hold	2,350	–	–	0.05%	227
2020 Q2	$151K	Buy	+2,350	New	+$129K	0.04%	236

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Exane Derivatives's MRNA Position: Q2 2022 in Review

Exane Derivatives increased its Moderna (MRNA) stake by 8.9% in Q2 2022, buying an estimated $50K and bringing the position to 4,267 shares worth $609K. The position accounts for 0.35% of the portfolio, ranked #64.

Exane Derivatives first reported a position in MRNA in Q2 2020 and has held it in 9 quarters since. The position peaked at $1.15M in Q1 2021. 982 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

Exane Derivatives held 4,267 shares of Moderna worth $609K as of Q2 2022.
Exane Derivatives bought 350 Moderna shares in Q2 2022, an estimated $50K.
Moderna made up 0.35% of Exane Derivatives's portfolio in Q2 2022, its #64 holding.
Exane Derivatives first reported a position in Moderna in Q2 2020 and has held it in 9 quarters since.
Exane Derivatives's Moderna position peaked at $1.15M in Q1 2021.
982 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.